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| INTRODUC TI ON
Atrial fibrillation (AF) is often triggered by atrial extrasystoles (AES), originating from the pulmonary vein (PV) area. 1 Isolation of these triggers, by means of creating circular lesions around the PVs, is a potential curative treatment modality for AF. Reported 1-year AF-free survival rates after PV isolation (PVI) vary from 50% to 81%. 2 AF recurs more frequently in patients with persistent AF (PeAF) than in patients with paroxysmal AF (PAF). 3 It is generally assumed that in the former group, AF is mediated by an arrhythmogenic substrate, rather than by triggers. Identification of individual patients at risk for AF recurrences remains challenging. Clinical markers associated with AF recurrence include atrial dilatation, valvular heart disease, and type of AF. 4 The value of daily AES frequency after PVI for AF recurrences has been investigated previously in patients with PAF. 5, 6 However, it is unknown whether AES frequency prior to PVI is a feasible marker to predict AF recurrence after PVI. Advanced atrial remodeling, caused by, for example, AF, might result in increased AES frequency. 7 If AES prior to PVI were to result from non-PV foci, this could relate to AF recurrence after PVI. Since remodeled patients are also more prone to develop recurrences, 3 AES frequency prior to PVI could be a noninvasive clinical marker that allows identification of subjects with a high risk for nonsuccessful PVI outcome.
Hence, AES frequency prior to PVI potentially allow early recognition of patients at risk for AF recurrence. Subsequently, this marker might be used to tailor treatment of AF to the individual patient. The aim of the current study was therefore to investigate whether AES frequency prior to PVI is associated with (timing of) development of AF in the blanking period and (timing of) AF recurrence during long-term follow-up, not only in patients with PAF but also PeAF.
| ME THODS
This retrospective, observational study is part of the "Arrhythmias Beta-blockers or other anti-arrhythmic agents were not withheld prior to PVI. Drugs were continued during the first 3 months and thereafter discontinued to discretion of the electrophysiologist.
Patients underwent an endovascular PVI by means of radiofrequency or cryoballoon ablation. Catheter manipulation was either manual or remotely controlled. In case of radiofrequency ablation, catheter navigation was supported by electroanatomical mapping.
Immediate procedural success was defined as the presence of an exit block.
All postprocedural rhythms from various rhythm recording devices, such as 12-lead surface ECG, continuous Holter registration, and implantable loop recorders, were evaluated for the presence of AF. 8, 9 The amount of AES on Holter recordings was standardized per 24 hours (AES/day). Since AES do not occur during AF episodes, Holter recordings with AF (either paroxysms or continuous) were not included for these calculations. A total AES count could not be retrieved in 13 patients. We defined AF recurrences according to the latest guidelines, hence any documented AF episode after the blanking period. 8, 9 Consequently, AF episodes within the 90 days blanking period were not considered AF recurrences. The study endpoint was AF recurrence.
All data were tested for normality. Normally distributed, continuous data are expressed as mean ± standard deviation, whereas dichotomous variables are depicted as number (percentage).
Comparison of these data was performed using, respectively, Students t test and χ 2 test. Nonparametric tests (including Kruskal-Wallis and Mann-Whitney U tests) were applied for comparison of continuous, skewed data, which are presented as median (interquartile range). Wilcoxon signed-rank test was performed to compare two related samples of continuous, skewed variables. Spearman's rank (ρ) was applied to test the correlation between non-normally distributed continuous variables and/or categorical parameters.
Since the amount of AES/day calculated from baseline Holter recordings is non-normally distributed, data in the amount of AES/day calculated from baseline Holter recordings, patients were categorized into quartiles of AES/day, to evaluate its effect on AF recurrences. AF-free survival after PVI in various patient categories was studied with Kaplan-Meier curves and log-rank testing. A P-value of .05 was considered statistically significant.
| RE SULTS
The total study population consisted of 684 patients (486 [71.1%] males). Clinical baseline characteristics of all patients are depicted in Table 1 . The majority of patients underwent cryoballoon ablation (N = 396, 57.9%). In 288 patients (42.1%), ablation was performed with radiofrequency energy, either manually (N = 211) or with magnetic (N = 47) or robotic (N = 30) navigation systems. AF was paroxysmal in 534 patients (78.1%), the remaining 150 patients (21.9%) had PeAF. Prior to PVI, ≥1 anti-arrhythmic drugs were used by 368 (93.3%) patients, as shown in Table 1 . Successful isolation of the PVs (criteria according to the recent AF guidelines) 8, 9 was achieved in all patients.
Electrophysiological parameters of all Holter recordings are summarized in Table 2 and PeAF (P = .053). Also, AES/day prior to PVI did not correlate with timing of AF episodes during the blanking period, in patients with PAF (P = .274) and patients with PeAF (P = .422).
Median follow-up time after PVI was 604 (177-1822) days.
Overall, AF recurred after the blanking period in 55.4% of the population (N = 379) at 203 (105-400) days after the procedure. The flowchart in Figure 1 shows the number of patients with AF episodes during the blanking period and AF recurrences for patients with paroxysmal or persistent AF separately. Furthermore, Figure 2 shows the fluctuations in the rhythm outcome per year of procedure for the overall study population (P = .003).
As illustrated in Figure 3 , AF recurred more frequently in pa- Overall, AES/day prior to PVI was not correlated with AF recurrence and time to first recurrence: ρ = 0.071, P = .203 and ρ = −0.055, P = .478. The left panel of Figure 5 shows that AF recurrences in patients with paroxysmal AF prior to PVI occur equally in all four quartiles of AES/day. The right panel depicts AF-free survival for patients with persistent AF. In both patient groups, AES/day prior to PVI did not correlate with either AF recurrence or time to recurrence (Table 3 ).
| D ISCUSS I ON
The present study demonstrates that AES/day prior to PVI is not correlated with (timing of) AF in the blanking period or with (timing of) AF recurrence in PAF. As expected, AF recurrences are more showed in a prospective study in 220 patients with PAF that ≥142 AES/day on the 6 months Holter recording was associated with a higher risk of AF recurrences after PVI (HR 2.84). However, the relation between AES prior to PVI and the long-term AF-free survival after PVI was not yet described. In this era of patient-tailored medicine, a more accurate estimation of the expected procedural outcome is desired for selecting the optimal strategy for each individual patient. Therefore, we examined whether a higher incidence of AES prior to PVI is associated with AF recurrences. Since this was not the case, it is most likely not a feasible marker in clinical practice.
Although it is generally assumed that AES in patients with AF mainly originate from the PV area, other origins, for example, the superior vena cava, have also been described. 1, 13, 14 After PVI, AES can either result from non-PV foci or from, for example, reconduction of the initially isolated PVs. In case these AES initiate AF episodes, additional ablation of these non-PVI foci could potentially cure AF patients with AF. In the present study, AF also recurred in the absence of PV reconduction. This suggests that AES initiating AF are most likely generated by non-PV foci. Besides the above mentioned non-PV foci, AES might also be generated by other atrial areas. It is generally accepted that AF episodes induce structural and electrical remodeling of the atria. 15, 16 As a result, cardiomyocyte hypertrophy, fibroblast proliferation, and deposition of extracellular matrix lead to separation of adjacent bundles of cardiomyocytes and subsequently conduction block. 17 Redistribution of cell-cell connexins and downregulation of ion channels also cause impaired conduction. 18 Next to these conduction abnormalities, coupling of myofibroblast and cardiomyocytes also facilitates induction of spontaneous ectopic activity. 7 An intracellular calcium overload, caused by atrial stress, may provoke delayed afterdepolarizations, which in turn can produce triggered activity. Altogether, this suggests that (micro)reentry and/or ectopic activity are more likely to occur in remodeled atria, which in turn may lead to an increased number of AES.
A 90 days blanking period after PVI is recommended in both European and American guidelines. 8, 9 AF episodes within this window may result from postprocedural inflammation, edema, or recovery phase. Arrhythmias in the blanking period would therefore be nonspecific and not directly related to treatment failure.
Nonetheless, episodes of AF or other arrhythmias during this blanking period are frequently reported. 19 In a recent study, Willems et al, 20 
| CON CLUS ION
The amount of AES/day prior to PVI is not correlated with (timing of) AF episodes in the blanking period, or with (timing of) AF recurrences and is therefore not suitable as a biomarker to identify PAF patients at risk for AF recurrences. However, patients with AF episodes during the blanking period develop AF recurrences earlier than patients without early AF episodes. 
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